AETHER BIOMACHINES


Associated tags: Biotechnology, Environment, Health, Fine chemical, Algorithm, Engineering, Enzyme, Biomachining, Hardware, Therapy, Nanotechnology, Software, Agriculture, Stanford University, AL, Computer, Massachusetts Institute of Technology, Information economy, Synthetic biology, Genetic engineering

Aether Biomachines and Allonnia Announce Partnership to Engineer Breakthrough Biological Solutions to Degrade PFAS and Other Harmful Environmental Toxins

Retrieved on: 
Tuesday, April 12, 2022
Biotechnology, Technology, Health, Other Natural Resources, Mining, Minerals, Agriculture, Natural Resources, Software, Nanotechnology, Environment, Hardware, Foam, Nature, CEO, Biotechnology, Filtration, Biomachining, Aether, Enzyme, Engineering, Technology, Environmental health, Drinking water, Environment, Solution, Algorithm, Nanotechnology, Partnership, Soil, Health, Therapy, Groundwater, PFAS, Fine chemical, Environmental remediation, Allonnia

The partnership leverages Aether and Allonnias existing technologies that are uniquely capable of degrading PFAS to drastically improve environmental health for millions of people across the world.

Key Points: 
  • The partnership leverages Aether and Allonnias existing technologies that are uniquely capable of degrading PFAS to drastically improve environmental health for millions of people across the world.
  • At Aether, we have prioritized environmental detoxification for better human health and are engineering breakthrough solutions that will finally allow the removal of harmful toxins from our environment, commented Pavle Jeremic, Founder and CEO of Aether Biomachines.
  • Aether is proud to partner with Allonnia to develop these novel, natural solutions and improve the lives of everyone, everywhere.
  • Allonnia, a company solving the worlds toughest waste problems using transformational biological solutions, has set its sights on developing a complete package for PFAS remediation.

Aether Biomachines Expands Board of Directors with Appointment of Ginkgo Bioworks Co-Founder Austin Che

Retrieved on: 
Wednesday, December 1, 2021
Software, Biotechnology, Pharmaceutical, Hardware, Health, Data Management, Technology, Genetics, Algorithm, AL, CEO, Environment, Computer, Technology, Massachusetts Institute of Technology, Industry, Biomachining, Information economy, Synthetic biology, Stanford University, Founder, Computer science, Therapy, Agriculture, Genetic engineering, Biotechnology, Board of directors, Board, Massachusetts, Psychology, Food, Teva Pharmaceuticals, Engineering, Partnership, Multimedia, Enzyme, Intelligence, Chemistry, Fine chemical, Management

Aether Biomachines, a leading enzyme engineering company building a future of abundance, today announced the appointment of Austin Che to its Board of Directors.

Key Points: 
  • Aether Biomachines, a leading enzyme engineering company building a future of abundance, today announced the appointment of Austin Che to its Board of Directors.
  • Che helped take Ginkgo Bioworks public in 2021 in a deal worth $15B and the company continues to produce custom organisms for a wide range of industries.
  • This holistic approach allows Aether to unlock novel chemistry that is impossible today and design new products and applications.
  • Aethers integrated technologies for intelligently searching and engineering enzyme sequences has enormous potential, said Austin Che.